TABLE 5

Treatments During the First Year After ESCF Enrollment According to Site Outcomes Quartile

TreatmentaOutcomes Quartile, n (%)Pb
UQ (N = 755)LQ (N = 743)
Intravenous antibiotics (at home)34 (4.5)18 (2.4).028.059
Intravenous antibiotics (at home or in hospital)183 (24.2)194 (26.1).40.50
Inhaled antibiotics72 (9.5)82 (11.0).34.12
Oral antibioticsc581 (77.0)553 (74.4).25.66
Airway clearance techniques/chest physiotherapy655 (86.8)697 (93.8)<.0001<.0001
Dornase alfa62 (8.2)77 (10.4).15.072
Bronchodilator, oral61 (8.1)53 (7.1).49.39
Bronchodilator, inhaled577 (76.4)626 (84.3).0001.0005
Corticosteroid, oral215 (28.5)130 (17.5)<.0001<.0001
Corticosteroid, inhaled141 (18.7)115 (15.5).10.28
Mast cell stabilizer260 (34.4)143 (19.2)<.0001<.0001
Nutrition, oral supplements273 (36.2)313 (42.1).018.011
Nutrition, enteral72 (9.5)77 (10.4).59.70
Pancreatic enzymes720 (95.4)734 (98.8)<.0001.0003
Mucolytics71 (9.4)8 (1.1)<.0001<.0001
Oxygen48 (6.4)22 (3.0).0018.0008
  • Site outcomes quartiles were determined on the basis of ranking the sites according to their median FEV1 % predicted in 2003 among 6- to 12-year-old patients who were enrolled in ESCF.

  • a Data that are n (%) reflect any reported usage of these treatments.

  • b P value in first column obtained from χ2 test. P value in second column obtained from multivariable logistic regression model controlling for quartile, non-Hispanic white, genotype, and age in months.

  • c Does not include oral quinolones.